ライフサイエンスコーパス: coagulant

1 ses, indicating a different activity of this coagulant.

2 ses, indicating a different activity of this coagulant.

3 ein was similar to that of a commercial milk coagulant.

4 ng ferric chloride, a common water treatment coagulant.

5 moved a humic-like group irrespective of the coagulant.

6 RNOM, Ca(2+) does not always act as a strong coagulant.

7 lecule in widespread clinical use as an anti-coagulant.

8 in conventional water facilities as primary coagulants.

9 chemical additives such as antiscalants and coagulants.

10 rentiate it from cheeses produced with other coagulants.

11 with polyaluminum chloride or ferric sulfate coagulants.

12 s, and there is a continual need to find new coagulants.

13 III (wt-fVIII) demonstrated similar specific coagulant activities but poor secretion of N1922S-fVIII.

14 nt with the bleeding disorder, the factor IX coagulant activities for wild-type (+/+), heterozygous (

15 Asn(2181) in human FV(a1) and have different coagulant activities.

16 t mediator of their pro-inflammatory and pro-coagulant activities.

17 a level of factor VII antigen and factor VII coagulant activity (<1 percent of normal) and suffers fr

18 prothrombin 20210A, and elevated factor VIII coagulant activity (factor VIII:c), these odds ratios we

19 ypotheses that elevated levels of factor VII coagulant activity (FVII:C), fibrinogen, and von Willebr

20 activated factor XII (FXIIa), and factor VII coagulant activity (FVIIc) are associated with higher ri

21 , 1.35, and 1.15 (P:<0.0001); for factor VII coagulant activity (FVIIc, % standard), 114.5, 116.2, an

22 Plasma factor VIII coagulant activity (FVIII:C) level is a highly heritable

23 rations (r = 0.48, P = 0.008) and factor VII coagulant activity (r = 0.46, P = 0.012) after adjustmen

24 on in the F7 gene that results in factor VII coagulant activity (VII:c) of less than 1% and VII antig

25 count (men, 1.68; women, 2.23), factor VIII coagulant activity (women, 1.25), and von Willebrand fac

26 ustained therapeutic expression of factor IX coagulant activity after gene transfer in 10 participant

27 in vivo with significantly reduced factor IX coagulant activity and a marked prolongation of the acti

28 ulation of adhesion molecule expression, pro-coagulant activity and inhibition of Toll-like receptor

29 The specific coagulant activity and the in vivo clearance and hemosta

30 ng concentrations of FVIIa exhibited similar coagulant activity as that of wild-type TF.

31 ivation, but also as a direct inducer of pro-coagulant activity associated with vascular and thrombot

32 Transgene-derived factor IX coagulant activity enabled the termination of baseline p

33 isplayed impaired adhesion, aggregation, and coagulant activity ex vivo that translated into defectiv

34 We further show that PDI suppresses TF coagulant activity in a nitric oxide-dependent pathway,

35 n 10 men with hemophilia B who had factor IX coagulant activity of 2% or less of the normal value.

36 , with a mean (+/-SD) steady-state factor IX coagulant activity of 33.7+/-18.5% (range, 14 to 81).

37 The effect of purified CpaA on the coagulant activity of FXII and the generation of bradyki

38 The coagulant activity of IXaWT was approximately 93%, of IX

39 These conditions increase the pro-coagulant activity of neutrophils, platelets, and red bl

40 inhibit endotoxin-induced tissue factor pro-coagulant activity of U937 cells.

41 apple domain (factor XI/PKA3) had <1% of the coagulant activity of wild type factor XIa in a plasma c

42 sulted in reduced adhesion, aggregation, and coagulant activity on collagen in vitro.

43 PDI enhanced TF coagulant activity on microvesicles shed from cells, sug

44 or VIIIa affinity and dramatically increased coagulant activity relative to factor IXa WT.

45 wed a 6- to 17-fold enhanced proteolytic and coagulant activity relative to mFVIIa, but increased ina

46 spholipid, FXI/PKA4 and FXI/PKA4-Gly326 have coagulant activity similar to FXI.

47 NP antibodies have in vitro anti-coagulant activity similar to those observed in anti-pho

48 ments contained higher TF protein levels and coagulant activity than equivalent linear areas.

49 rom inactivation/inhibition; (3) restricting coagulant activity to the site of vascular injury; and (

50 Its coagulant activity was enhanced in all types of plasma a

51 Coagulant activity was moderately (N129A, K132A, K126A)

52 Factor IX coagulant activity was normal in samples from donors wit

53 Vector-derived factor IX coagulant activity was sustained in all the participants

54 antigen (VWF:Ag), multimers, and factor VIII coagulant activity were virtually absent.

55 s soluble, circulates in blood, exhibits pro-coagulant activity when exposed to phospholipids, and is

56 is equivalent to about a 5-fold increase in coagulant activity when stimulated platelets are compare

57 or moderately severe hemophilia B (factor IX coagulant activity, <=2% of the normal value) received f

58 ke is an important determinant of factor VII coagulant activity, a hemostatic risk factor for fatal i

59 w patients with isolated defects in platelet coagulant activity, and compared with that in Scott synd

60 gl2 is IFN gamma-inducible, possesses direct coagulant activity, and inhibits T cell proliferation an

61 of the heat treatment and levels of residual coagulant activity, breakdown of proteins and formation

62 related to defective expression of membrane coagulant activity, circulating blood cells show decreas

63 ibited both EMT-associated TF expression and coagulant activity, further strengthening the link betwe

64 n III, an endogenous inhibitor of thrombin's coagulant activity, is an equally effective inhibitor of

65 l thromboplastin time, d-dimers, factor VIII coagulant activity, plasma von Willebrand factor (VWF) a

66 Although the polysaccharide showed some anti-coagulant activity, small oligosaccharide fCS fragments

67 Cl(2) markedly increased the cell-surface TF coagulant activity, the increase is associated with incr

68 c phospholipids, attenuated the increased TF coagulant activity.

69 either type 1 immunity or immune-associated coagulant activity.

70 NP1 treatment did not show off target anti-coagulant activity.

71 use APC seemed to be independent of its anti-coagulant activity.

72 f the A3 domain markedly decreased factor XI coagulant activity.

73 factor (TF) and exhibited similar extrinsic coagulant activity.

74 1), or fibrinogen concentrations; factor VII coagulant activity; or plasminogen activator inhibitor t

75 loop of IXaE245V with a concomitant loss of coagulant activity; this proteolysis was moderate in IXa

76 The influence of simultaneous coagulant addition on PAC adsorption of micropollutants

77 reference for this moiety was supported by a coagulant-affinity factor derived from the association b

78 gnificantly with the inclusion of an anionic coagulant aid and slightly with a cationic coagulant aid

79 c coagulant aid and slightly with a cationic coagulant aid.

80 igated to determine the effects of different coagulant aids (anionic, cationic, and nonionic polymers

81 It was shown that coagulants and coagulant aids applied to OSPW feedwater can affect memb

82 Among three coagulant aids tested, anionic coagulant aids led to the most enhanced membrane perform

83 OSPW turbidity, the application of cationic coagulant aids promoted the adsorption of foulants on me

84 Among three coagulant aids tested, anionic coagulant aids led to the

85 Conversely, although cationic coagulant aids were the most effective in reducing OSPW

86 thod based on the simultaneous use of Fe(II) coagulant and an oxidant to enhance conventional coagula

87 rgoes proteolytic irreversible activation by coagulant and anti-coagulant proteases.

88 roprotective effect is secondary to its anti-coagulant and anti-inflammatory effects.

89 Activated protein C (APC) is a systemic anti-coagulant and anti-inflammatory factor.

90 A timely institution of anti-coagulant and anti-tubercular treatment led to a complet

91 Viper venom induced haemorrhagic, coagulant and anticoagulant activities were effectively

92 gulation of other plasma proteins, including coagulant and anticoagulant factors.

93 nciples of proteolytic cell signaling of the coagulant and anticoagulant pathways.

94 receptor that elicits cellular responses to coagulant and anticoagulant proteases.

95 s perinecrotic regions were enriched for pro-coagulant and DNA damage response proteins.

96 ELOX(TM)-gauze, the MACS provides higher pro-coagulant and hemostatic capacities in lethally normal a

97 The coagulant and hemostatic effects of rFIX and pdFIX were

98 The coagulant and inflammatory exacerbation in sepsis is cou

99 ibition of APC function exacerbates both the coagulant and inflammatory responses of the animals to s

100 o bacterial challenge, exacerbating both the coagulant and inflammatory responses.

101 ve TGF-beta(1) concentrations and factor VII coagulant and plasminogen activator inhibitor type 1 act

102 As they are pro-coagulant and potentially pro-inflammatory, rapid cleara

103 otein disulfide isomerase (PDI) regulates TF coagulant and signaling activities by targeting this dis

104 It was shown that coagulants and coagulant aids applied to OSPW feedwater

105 The usage of coagulants and flocculants at optimum conditions has bee

106 and pressure of 1 atm along with addition of coagulants and flocculants in the wastewater.

107 nd roughness of MPs impacted MP affinity for coagulants and flocculants.

108 an those of commonly applied iron-containing coagulants and the formation of ferrimagnetic species pr

109 on parameters of lung AR relate to the anti-coagulant, anti-inflammatory, and possibly immunoregulat

110 lowing variables: use of aspirin/NSAIDs/anti-coagulants/anti-platelets, pathologic diagnoses (includi

111 lp practitioners use anticoagulation and pro-coagulants appropriately in patients with cirrhosis.

112 ated a novel semi-automated in-syringe-based coagulant-assisted liquid-liquid microextraction (IS-CGA

113 cological perturbations of the intravascular coagulant balance were combined with genetic mouse model

114 ereas rPAR1(T) is not a substrate for weakly coagulant beta-thrombin.

115 The type of coagulant (bovine or vegetable) had no significant effec

116 ns, the pesticide paraquat, and heparin anti-coagulants by the PK approach.

117 In contrast, the anti-inflammatory/anti-coagulant CD141/thrombomodulin increased markedly when I

118 between plastic surfaces and aluminum-based coagulants compared to cationic polyacrylamide (PAM).

119 r study comparing 6 months of anti-inhibitor coagulant complex (AICC), infused prophylactically at a

120 hemostasis proceeds through the assembly of coagulant complexes on a lipid surface derived from acti

121 Optimum coagulant concentration (OCC) decreased with increasing

122 ased aggregation rate and increased critical coagulant concentration required for diffusion-limited a

123 In addition to IL-1beta, pro-coagulant concentrations of thrombin or fresh platelets

124 od microfluidics, employing coagulant or non-coagulant conditions at physiological temperature, we ob

125 gh-altitude conditions and discusses the pro-coagulant consequences induced by environmental disturba

126 PKA did not correct the coagulant defect in factor XII deficient plasma, was pur

127 Accordingly, the coagulant demand increased by 1.5 and 3.8x for the water

128 Prophylactic anti-coagulants did not affect symptomatic central venous thr

129 onal strategy to deliver locally-active anti-coagulants directly within grafts and decrease microvasc

130 Minus Approach avoids primary chemical-based coagulants, disinfectants, and advanced oxidation proces

131 lly removed humic substances and reduced the coagulant dose needed for colloidal NOM removal as a res

132 ctively remove colloidal NOM and the optimal coagulant dose was primarily determined by the concentra

133 resholds for color, total organic carbon and coagulant dose.

134 X and coagulation pretreatment at much lower coagulant doses was as effective as coagulation in reduc

135 emical and electrodissolution contributed to coagulant dosing since measured aluminum concentrations

136 both unliganded and in complex with the anti-coagulant drug warfarin.

137 ic activity was inhibited by dicumarol, anti-coagulant drug, with IC50 of 4 microm.

138 Although commonly used anti-coagulant drugs, such as low molecular weight heparin an

139 rs showed that the aPL mAbs reduced the anti-coagulant effect of annexin A5 and promoted thrombin gen

140 which activates deleterious inflammatory and coagulant effector mechanisms, is an effective molecular

141 y higher avidity binding to FXa with greater coagulant effects compared to systemic lupus erythematos

142 syndrome, suggesting that they may have pro-coagulant effects in polyp tissue.

143 The coagulant effects of PDI inhibition were sensitive to an

144 In every case examined, coagulant efficiency increased when the plastic surface

145 Identifying the leading factors to a pro-coagulant environment in each case-mechanical or biochem

146 suitability of a PARAFAC-based approach for coagulant evaluation/selection was demonstrated when com

147 er self-proteins involved in inflammatory or coagulant events.

148 Administration of coagulant factor VIIa significantly attenuated the DSS-i

149 ding disorders caused by a deficiency in pro-coagulant factor VIII or IX that is treated by downregul

150 Secondary hemostasis assessment included pro-coagulant (factor VIII and factor XIII) and anti-coagula

151 including the binding constants (Kd) of the coagulant factors for the lipid surface.

152 theoretical concerns about the impact of pro-coagulant factors in convalescent plasma on the coagulat

153 ression while inducing the expression of pro-coagulant factors.

154 cell shrinkage occurring in the presence of coagulant fixative.

155 Although the size of nano-scale primary coagulant flocs changed little by the addition of NaClO,

156 enhances the bonding with, and between, the coagulant flocs; EPS together with smaller sizes of the

157 Its flowers, used as a vegetable coagulant for gourmet cheese production, are rich in asp

158 imidazole (APIm) is proposed as a reversible coagulant for harvesting microalgae.

159 ur results demonstrated that PGA is a potent coagulant for the coacervation of 7S, 11S, daidzein and

160 uction of hard cheese using either microbial coagulants from Rhyzomucor miehei (MC) or calf rennet (C

161 DOM) in a multicoagulant (two aluminum-based coagulants) full scale drinking water treatment plant.

162 ivary-expressed apyrases, which have an anti-coagulant function in blood-feeding arthropods.

163 Xa activation of PAR-1 but does not enhance coagulant function of factor Xa.

164 antigen levels >40% in the absence of FVIII coagulant function were detected in the circulation for

165 ibrinolytic activity and lipemia, factor VII coagulant (FVII:c) activity, and activated FVII (FVIIa)

166 activated factor VII activity (FVIIa), FVII coagulant (FVIIC) activity, FVIII coagulant (FVIIIC) act

167 enotype is a major determinant of factor VII coagulant (FVIIc) activity, which is associated with an

168 IIa), FVII coagulant (FVIIC) activity, FVIII coagulant (FVIIIC) activity, tissue factor pathway inhib

169 rom plant sources have been proposed as milk coagulants, however, limited research has been done on t

170 us hold the best potential for use as a milk coagulant in cheese production.

171 pis procera extract can be used as effective coagulant in cheesemaking.

172 roteases could potentially be used as a milk coagulant in cheesemaking.

173 sphonate-based antiscalants and ferric-based coagulants in the porewater, may change the redox zones

174 most TF on cell surfaces exists in a cryptic coagulant-inactive state but are transformed to a procoa

175 Not only was this coagulant increase costly for the utility, it also resul

176 an endogenous inhibitor of factor Xa and the coagulant initiator complex tissue factor/factor VIIa.

177 n 2 (CFHR2, related to complement system and coagulant mechanism) were selected for further ELISA val

178 Both alpha-thrombin and weakly coagulant meizothrombin-des-fragment-1 (mu-thrombin) hyd

179 sel-Ig contained higher concentration of pro-coagulant microparticles and clotted one minute faster t

180 irculates, although it may be present in pro-coagulant microparticles.

181 UMC > 0.98), and a comparable effect of both coagulants on the structure (UMC > 0.99) and distributio

182 he gene silencing had no effect on either TF coagulant or cell signaling functions.

183 h-shear whole-blood microfluidics, employing coagulant or non-coagulant conditions at physiological t

184 at the cross-roads of both the pro- and anti-coagulant pathways.

185 Pretreating organs with novel cytotopic anti-coagulant peptides that localise to endothelial cell mem

186 This pro-coagulant phenotype of DeltaCT mice could be reversed by

187 ighlights the potential use of a phosphonium coagulant polymer, polyDADEPC, as a viable alternative t

188 levels of recombinant FVIIa can restore the coagulant potential of saliva of persons with FVII defic

189 roenvironment of the sacrificial anode where coagulant precursors are dissolved leading to better des

190 re COVID disease by reducing infiltration of coagulants, preventing prothrombin activation and fibrin

191 transfusion practices for both platelets and coagulant products (e.g., fresh-frozen plasma and recomb

192 PC functions as an anti-coagulant, profibrinolytic, and anti-inflammatory agent,

193 er complex was generated, which explains the coagulant properties and efficient Fbg conversion.

194 ects (< 5%), as well as non-adhesive and non-coagulant properties in contact with lung endothelial ce

195 en C19MC oncogenic miRNAs (oncomirs) and the coagulant properties of cancer cells, a question previou

196 EMT transcription factor Snail increased TF, coagulant properties, and early metastasis.

197 Activation of PAR1 by the coagulant protease thrombin results in Ras homolog gene

198 (PAR1), a G protein-coupled receptor for the coagulant protease thrombin, is irreversibly activated b

199 a G-protein-coupled receptor (GPCR) for the coagulant protease thrombin.

200 AR1) is a G protein-coupled receptor for the coagulant protease thrombin.

201 s activated by thrombin whereas the upstream coagulant protease VIIa bound to tissue factor and Xa ca

202 Activated protein C (APC), an anti-coagulant protease, also activates PAR(1).

203 Thrombin, a coagulant protease, induces inflammatory responses and e

204 eceptors that transmit cellular responses to coagulant proteases in a variety of cell types in the va

205 and functions as the endogenous receptor for coagulant proteases VIIa and Xa in these cells.

206 rs that function as cell-surface sensors for coagulant proteases, as well as other proteases associat

207 rreversible activation by coagulant and anti-coagulant proteases.

208 blood coagulation factor IX (hFIX) and anti-coagulant protein C (hPC) genes, previously shown to hav

209 inhibitors directed against the factor VIII coagulant protein is one of the most challenging and exp

210 er are to produce therapeutic amounts of the coagulant protein while minimizing an immune response or

211 equire lipolysis and the presence of another coagulant protein, factor IX.

212 n thrombin-induced thromboembolism, factor X coagulant protein-induced thrombosis, and endotoxin-indu

213 ulant (factor VIII and factor XIII) and anti-coagulant (protein C, protein S, and antithrombin) facto

214 Thrombin and factor Xa, two important pro-coagulant proteinases, can be regulated through direct a

215 hat is critical for pro-inflammatory and pro-coagulant reactions.

216 eparation using centrifugation for dissolved coagulant recovery.

217 ted that the Procr+/- genotype increased the coagulant response relative to wild-type mice.

218 They also exhibited a similar coagulant response upon factor Xa/phospholipid infusion.

219 ence protein C activation and exaggerate the coagulant response.

220 t protease inhibitor in the inflammatory and coagulant responses to septic illness have not been eval

221 Thrombin is a pro-coagulant serine protease, which causes the local loss o

222 on capacity associated with higher available coagulant surface area, (iii) greater virus-floc binding

223 lex interaction between the inflammatory and coagulant systems in sepsis pathophysiology has resulted

224 nary TF-FVIIa-FXa complex but not by the non-coagulant TF-FVIIa binary complex.

225 rotein carboxylation and Warfarin-based anti-coagulant therapies that need to be considered both retr

226 travascular thrombin concentrations exceed a coagulant threshold.

227 As expected, the mean F.IX coagulant titer of affected male mice was 2.8 U/dL (n =

228 Coagulant type and hydrocolloid addition significantly i

229 environmental processes and in the action of coagulants used in water and wastewater treatment.

230 This study explored the effects of coagulants (vinegar, lemon juice, and gluconolactone [GD

231 In particular, the anti-coagulant warfarin is prescribed to over 15 million peop

232 ently the optimal temperature of immobilized coagulant was defined and a technically-friendly enzyme

233 The active coagulant was extracted from the seeds and analyzed for

234 Cancer pro-coagulant was localized to tumor cells in several cases

235 The recovered coagulant was then reused for treating primary wastewate

236 Experiments indicated alum, an inexpensive coagulant, was able to remove residual Mn species produc

237 sludge and its reuse potential as secondary coagulant were investigated.

238 However, conventional coagulants, widely employed in water treatment plants gl

239 olytics, and down-regulation of natural anti-coagulants, with protein C (PC) being a critical example

240 In an effort to develop green coagulant without compromising cost, this research inves